Operating Expenses
Acquired IPR&D Expense
Vertex Pharmaceuticals Acquired IPR&D Expense decreased by 99.1% to $500.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 97.5%, from $19.80M to $500.00K. Over 4 years (FY 2021 to FY 2025), Acquired IPR&D Expense shows a downward trend with a -41.2% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2021
Last reportedQ1 2026May 5, 2026
Metric ID:
abbv_acquired_iprd_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $278.33M | $278.33M | $278.33M | $2.00M | $61.90M | $29.00M | $22.60M | $347.10M | $110.50M | $51.70M | $17.80M | $76.80M | $4.45B | $15.00M | $87.50M | $19.80M | $2.20M | $54.50M | $56.50M | $500.00K |
| QoQ Change | — | +0.0% | +0.0% | -99.3% | >999% | -53.2% | -22.1% | >999% | -68.2% | -53.2% | -65.6% | +331.5% | >999% | -99.7% | +483.3% | -77.4% | -88.9% | >999% | +3.7% | -99.1% |
| YoY Change | — | — | — | — | -77.8% | -89.6% | -91.9% | >999% | +78.5% | +78.3% | -21.2% | -77.9% | >999% | -71.0% | +391.6% | -74.2% | -100.0% | +263.3% | -35.4% | -97.5% |
Range$500.00K – $4.45B
CAGR-73.6%
Avg YoY Growth>999%
Median YoY Growth-53.2%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Pharmaceuticals | $19.80M | $2.20M | $54.50M | $56.50M | $500.00K |
| Total | $19.80M | $2.20M | $54.50M | $56.50M | $500.00K |
Acquired IPR&D Expense at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's acquired ipr&d expense?
- Vertex Pharmaceuticals (VRTX) reported acquired ipr&d expense of $500.00K in Q1 2026.
- How has Vertex Pharmaceuticals's acquired ipr&d expense changed year-over-year?
- Vertex Pharmaceuticals's acquired ipr&d expense decreased by 97.5% year-over-year, from $19.80M to $500.00K.
- What is the long-term trend for Vertex Pharmaceuticals's acquired ipr&d expense?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's acquired ipr&d expense has grown at a -41.2% compound annual growth rate (CAGR), from $1.11B to $133.00M.